Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of 1,6-Hexanediol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL3846619 | 1.00 | TP53 (0.61) | TP53GPR84FFAR1FFAR4LMNA | |
| Lactic Acid SCHEMBL8850880 | 0.97 | TP53 (0.65) | TP53GPR84FFAR1FFAR4LMNA | |
| Lactic Acid SCHEMBL11019396 | 0.97 | TP53 (0.65) | TP53GPR84FFAR1FFAR4LMNA | |
| 1,6-Hexanediol SCHEMBL3482756 | 0.93 | TP53 (0.52) | TP53GPR84FFAR1FFAR4LMNA | |
| Lactic Acid SCHEMBL27704429 | 0.92 | TP53 (0.65) | TP53GPR84FFAR1FFAR4OR51E2 | |
| Cetostearyl Alcohol SCHEMBL28027646 | 0.91 | LMNA (0.59) | TP53GPR84FFAR1LMNAALDH1A1 | |
| Dodecanol SCHEMBL27487450 | 0.91 | LMNA (0.59) | TP53GPR84FFAR1LMNAALDH1A1 | |
| Lactic Acid SCHEMBL29116772 | 0.91 | LMNA (0.59) | TP53GPR84FFAR1LMNAALDH1A1 | |
| Myristyl Alcohol SCHEMBL27503558 | 0.91 | LMNA (0.59) | TP53GPR84FFAR1LMNAALDH1A1 | |
| Myristyl Alcohol SCHEMBL28076392 | 0.91 | LMNA (0.59) | TP53GPR84FFAR1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130345260-A1 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device | DURECT CORPORATION (US) | 2013-12-26 | — | — | US | disclosed |
| US-7833543-B2 | Sustained release of active materials; storage stability | DURECT CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080152708-A1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION | 2008-06-26 | — | — | US | disclosed |
| US-20080145419-A1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-20060210599-A1 | Injectable or sprayable nonpolymeric ester or mixed ester solution easily formulated with therapeutic agents | GIBSON JOHN W | 2006-09-21 | — | — | US | disclosed |
| US-7053209-B1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION (US) | 2006-05-30 | — | — | US | disclosed |
| US-6413536-B1 | DELIVERING ACTIVE MATERIALS | SOUTHERN BIOSYSTEMS, INC. | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210599-A1 | Injectable or sprayable nonpolymeric ester or mixed ester solution easily formulated with therapeutic agents | MMP1, MMP11, MMP13 | TP53 1789/4885GPR84 1897/4885FFAR1 1550/4885 |
| US-20080152708-A1 | High viscosity liquid controlled delivery system and medical or surgical device | MMP1, MMP13, MMP9 | TP53 1769/4885GPR84 2110/4885FFAR1 4101/4885 |
| US-20130345260-A1 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device | MMP1, MMP13, MMP9 | TP53 1783/4885GPR84 2124/4885FFAR1 4158/4885 |
| US-20080145419-A1 | High viscosity liquid controlled delivery system and medical or surgical device | MMP1, MMP13, MMP9 | TP53 1769/4885GPR84 2110/4885FFAR1 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.